Medical Device

Thermo Fisher Scientific Inc. the world leader in serving science, today announced the launch of Managed Equipment Solutions a new subscription-based offering that bundles instrument and equipment procurement with consumables, applications support, software, training and extended service in a convenient and cost-efficient agreement. Managed Equipment Solutions is ideal for biopharma companies, academic ...

- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the launch of Managed Equipment Solutions a new subscription-based offering that bundles instrument and equipment procurement with consumables, applications support, software, training and extended service in a convenient and cost-efficient agreement.

Managed Equipment Solutions (MES) is ideal for biopharma companies, academic institutions, healthcare organizations and industrial businesses seeking innovative procurement models that offer all the benefits of premium instrument procurement but with increased flexibility. MES gives customers in research, life sciences, specialty diagnostics and applied markets the assurance of long-term, consistent analytical technology performance with predictable subscription costs and a pathway to future innovation.

"Managed Equipment Solutions is a direct result of our customers asking for a value-added offering that gives them convenient and timely access to our latest instrumentation and equipment innovations," said Dan Shine , senior vice president, and president of Thermo Fisher's Analytical Instruments business. "Through a predictable, fixed-budget subscription, customers can bundle premium technology with all the associated products and services required to support their workflows now, as well as in the future as their research and application needs evolve."

As an integrated solution, MES can reduce total cost of ownership while preserving capital budgets. Meanwhile, it protects against technology obsolescence by enabling customers to upgrade their instruments and equipment every three to five years. MES is provided through a single, easy to manage agreement, resulting in a highly streamlined procurement process.

For more information, please visit https://www.thermofisher.com/us/en/home/products-and-services/services/financial-leasing-services/managed-equipment-solutions.html .

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion . Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com .

Media Contact Information:
Charlotte McCormack
Phone: 781-622-1202
E-mail: charlotte.mccormack@thermofisher.com

Cision View original content to download multimedia: http://www.prnewswire.com/news-releases/thermo-fisher-scientific-offers-financial-flexibility-with-new-managed-equipment-solutions-301201400.html

SOURCE Thermo Fisher Scientific

News Provided by PR Newswire via QuoteMedia

Abbott Reports Strong Fourth-Quarter 2021 Results; Issues 2022 Forecast

Abbott (NYSE: ABT) today announced financial results for the fourth quarter and full year ended Dec. 31, 2021 and issued its financial outlook for 2022.

  • Fourth-quarter sales of $11.5 billion increased 7.2 percent on a reported basis and 7.7 percent on an organic basis, which excludes the impact of foreign exchange.
  • Fourth-quarter GAAP diluted EPS was $1.11 and adjusted diluted EPS, which excludes specified items, was $1.32 .
  • Full-year 2021 GAAP diluted EPS from continuing operations was $3.94 and adjusted diluted EPS from continuing operations was $5.21 , reflecting 42.7% growth versus the prior year. 1
  • Global COVID-19 testing-related sales were $2.3 billion in the fourth quarter and $7.7 billion for the full-year. Abbott has distributed more than 1.4 billion COVID-19 tests since the start of the pandemic.
  • Abbott issues full-year 2022 guidance for diluted EPS from continuing operations on a GAAP basis of at least $3.43 and full-year adjusted diluted EPS from continuing operations of at least $4.70 .
  • Full-year 2022 guidance includes an initial COVID-19 testing-related sales forecast of $2.5 billion , which Abbott expects to occur early in the year and will update on a quarterly basis.
  • Abbott's R&D pipeline continues to deliver a steady cadence of new products. Select 2021 highlights include U.S. Centers for Medicare & Medicaid Services expanded reimbursement for MitraClip ® , U.S. launches of Amplatzer ® Amulet ® , NeuroSphere Virtual Clinic, and Portico ® transcatheter aortic valve replacement (TAVR) system, along with the international launch of Navitor TAVR system.

"2021 was an outstanding year for Abbott," said Robert B. Ford , chairman and chief executive officer, Abbott. "We achieved more than 40 percent EPS growth, exceeding the baseline EPS guidance we set at the beginning of last year and, importantly, continued to advance our new product pipeline across the portfolio."

Keep reading... Show less
Avricore Health CEO and Special Guests Join Radius Research for Investor Update

Avricore Health CEO and Special Guests Join Radius Research for Investor Update

Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") is excited to be joined by Shoppers Drug Mart Pharmacist and Associate Owner, Mohamad Adel Elsabakhawi and Abbott Rapid Diagnostics' General Manager Daniel St. Pierre and National Sales Manager, Soul Khan.

"The Company enjoyed an incredible year in 2021, and throughout the Holidays and the beginning of the New Year, we have continued to finalize key agreements which will lead to substantial growth this year." said Avricore Health CEO, Hector Bremner. "Our partners are as excited as we are and we look forward to deepening our collaboration."

Keep reading... Show less

Johnson & Johnson Reports Q4 and Full-Year 2021 Results

- Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2021. "Our 2021 performance reflects continued strength across all segments of our business. Guided by Our Credo, I am honored to assume the role of CEO, leading our global teams in continuing our work to deliver life-changing solutions to consumers, patients, and health care providers" said Joaquin Duato Chief Executive Officer. "Given our strong results, financial profile, and innovative pipeline we are well positioned for success in 2022 and beyond."

OVERALL FINANCIAL RESULTS

Keep reading... Show less
Bloom logo

Bloom Health Partners Receives DTC Eligibility

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company"), a global platform for operational health, is pleased to announce that its common shares are now eligible for electronic clearing and settlement through the Depository Trust Company ("DTC"), a subsidiary of the Depository Trust & Clearing Corp. that manages the electronic clearing and settlement of publicly-traded companies in the United States.

The Company's shares will continue to trade in the USA, under the ticker BLMHF on the OTCQB Market. DTC eligibility reduces costs and accelerates the settlement process for investors and brokers allowing the Company's common shares to be traded over a much wider selection of brokerage firms by coming into compliance with their requirements.

Keep reading... Show less

Dr. Yehia Hashad Will Join Bausch + Lomb Corporation as Executive Vice President of Research & Development and Chief Medical Officer

Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health") has announced that Dr. Yehia Hashad will join Bausch + Lomb Corporation ("Bausch + Lomb") as executive vice president of Research & Development (R&D) and chief medical officer (CMO) effective Jan. 31, 2022 .

Dr. Hashad will join Bausch + Lomb from Allergan/AbbVie, where for the past 11 years he held various roles, including leading Allergan's global clinical development program for its eye care portfolio. Prior to that, he was with Novartis Pharma AG for five years, where he focused on ophthalmology, and also with T3A Pharma Group for nearly 10 years.

Keep reading... Show less

Latest Press Releases

Related News

×